CANCER:

Anaplastic Astrocytoma

Related cancers:

‹

Astrocytoma (34)

Astrocytoma (34)

›

No biomarker No biomarker	Anaplastic Astrocytoma Anaplastic Astrocytoma	No biomarker No biomarker	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval	temozolomide Sensitive: A1 - Approval
No biomarker No biomarker	Anaplastic Astrocytoma Anaplastic Astrocytoma	No biomarker No biomarker	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: A2 - Guideline	PCV Sensitive: A2 - Guideline
IDH1 R132H IDH1 R132H	Anaplastic Astrocytoma Anaplastic Astrocytoma	IDH1 R132H IDH1 R132H	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials	temozolomide Sensitive: B - Late Trials
MGMT promoter methylation MGMT promoter methylation	Anaplastic Astrocytoma Anaplastic Astrocytoma	MGMT promoter methylation MGMT promoter methylation	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials	temozolomide Sensitive: B - Late Trials
BRAF V600 BRAF V600	Anaplastic Astrocytoma Anaplastic Astrocytoma	BRAF V600 BRAF V600	Anaplastic Astrocytoma Anaplastic Astrocytoma	vemurafenib Sensitive: C1 - Off-label	vemurafenib Sensitive: C1 - Off-label
NRAS mutation NRAS mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	NRAS mutation NRAS mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials	atezolizumab + cobimetinib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	IDH2 mutation IDH2 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials	PCV Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	IDH1 mutation IDH1 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials	PCV Sensitive: C3 – Early Trials
ABCB1 G412G ABCB1 G412G	Anaplastic Astrocytoma Anaplastic Astrocytoma	ABCB1 G412G ABCB1 G412G	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: C3 – Early Trials	temozolomide Sensitive: C3 – Early Trials
TMB-H TMB-H	Anaplastic Astrocytoma Anaplastic Astrocytoma	TMB-H TMB-H	Anaplastic Astrocytoma Anaplastic Astrocytoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
NACC2-NTRK2 fusion NACC2-NTRK2 fusion	Anaplastic Astrocytoma Anaplastic Astrocytoma	NACC2-NTRK2 fusion NACC2-NTRK2 fusion	Anaplastic Astrocytoma Anaplastic Astrocytoma	larotrectinib Sensitive: C4 – Case Studies	larotrectinib Sensitive: C4 – Case Studies
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	carboplatin + temozolomide + vincristine Resistant: C4 – Case Studies	carboplatin + temozolomide + vincristine Resistant: C4 – Case Studies
BRAF mutation BRAF mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	BRAF mutation BRAF mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	dabrafenib Sensitive: C4 – Case Studies	dabrafenib Sensitive: C4 – Case Studies